May is Mental Health Awareness Month as well as Older Americans Month. This critical intersection implores us to explore emotional…more.
Rally for Access
Published March 24, 2022
In June 2021, the Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s disease–the first new therapy Alzheimer’s therapy in almost 20 years. But in January 2022, the Centers for Medicare and Medicaid Services (CMS) announced it has no plans to cover the treatment for most seniors. Even worse, CMS’ decision will extend to future FDA approved Alzheimer’s treatments in this class of drugs. So on March 15, 2022, patients and advocates gathered to make sure their voices were heard. This video shares highlights from the rally.
Related Alzheimer’s Disease Videos
Atrial fibrillation (AFib) is one of the most common types of arrhythmias—or irregular heartbeats—and causes the heart to…more.
Alzheimer’s Disease Policy Task Force
The Alzheimer’s Disease Policy Task Force is an ad hoc coalition of patient, family caregiver, and professional organizations, working collectively to organize and educate the Alzheimer’s disease community and decisionmakers on the Food & Drug Administration’s (FDA) Accelerated Approval pathway, and the Centers for Medicare & Medicaid Services’ (CMS) coverage determination processes for amyloid-targeted monoclonal antibody therapies for the treatment of Alzheimer’s disease.